Kang L, Zheng M Q, Morishima M, Wang Y, Kaku T, Ono K
Department of Pathophysiology, Oita University School of Medicine, Oita 879-5593, Japan.
Br J Pharmacol. 2009 Jun;157(3):404-14. doi: 10.1111/j.1476-5381.2009.00174.x. Epub 2009 Apr 9.
Bepridil is an anti-arrhythmic agent with anti-electrical remodelling effects that target many cardiac ion channels, including the voltage-gated Na+ channel. However, long-term effects of bepridil on the Na+ channel remain unclear. We explored the long-term effect of bepridil on the Na+ channel in isolated neonatal rat cardiomyocytes and in a heterologous expression system of human Na(v)1.5 channel.
Na+ currents were recorded by whole-cell voltage-clamp technique. Na+ channel message and protein were evaluated by real-time RT-PCR and Western blot analysis.
Treatment of cardiomyocytes with 10 micromol.L(-1) bepridil for 24 h augmented Na+ channel current (I(Na)) in a dose- and time-dependent manner. This long-term effect of bepridil was mimicked or masked by application of W-7, a calmodulin inhibitor, but not KN93 [2-[N-(2-hydroxyethyl)-N-(4-methoxy benzenesulphonyl)]-amino-N-(4-chlorocinnamyl)-N-methylbenzylamine], a Ca2+/calmodulin-dependent kinase inhibitor. During inhibition of protein synthesis by cycloheximide, the I(Na) increase due to bepridil was larger than the increase without cycloheximide. Bepridil and W-7 significantly slowed the time course of Na(v)1.5 protein degradation in neonatal cardiomyocytes, although the mRNA levels of Na(v)1.5 were not modified. Bepridil and W-7 did not increase I(Na) any further in the presence of the proteasome inhibitor MG132 [N-[(phenylmethoxy)carbonyl]-L-leucyl-N-[(1S)-1-formyl-3-methylbutyl]-L-leucinamide]. Bepridil, W-7 and MG132 but not KN93 significantly decreased 20S proteasome activity in a concentration-dependent manner.
We conclude that long-term exposure of cardiomyocytes to bepridil at therapeutic concentrations inhibits calmodulin action, which decreased degradation of the Na(v)1.5 alpha-subunit, which in turn increased Na+ current.
苄普地尔是一种抗心律失常药物,具有抗电重构作用,可作用于多种心脏离子通道,包括电压门控钠通道。然而,苄普地尔对钠通道的长期影响仍不清楚。我们在新生大鼠离体心肌细胞和人Na(v)1.5通道的异源表达系统中探讨了苄普地尔对钠通道的长期影响。
采用全细胞膜片钳技术记录钠电流。通过实时逆转录聚合酶链反应和蛋白质印迹分析评估钠通道的信息和蛋白。
用10微摩尔·升-1苄普地尔处理心肌细胞24小时,钠通道电流(I(Na))以剂量和时间依赖性方式增加。苄普地尔的这种长期作用可被钙调蛋白抑制剂W-7模拟或掩盖,但不能被Ca2+/钙调蛋白依赖性激酶抑制剂KN93 [2-[N-(2-羟乙基)-N-(4-甲氧基苯磺酰基)]-氨基-N-(4-氯肉桂基)-N-甲基苄胺]模拟或掩盖。在用环己酰亚胺抑制蛋白质合成期间,苄普地尔引起的I(Na)增加大于未用环己酰亚胺时的增加。苄普地尔和W-7显著减慢了新生心肌细胞中Na(v)1.5蛋白降解的时间进程,尽管Na(v)1.5的信使核糖核酸水平未改变。在蛋白酶体抑制剂MG132 [N-[(苄氧基)羰基]-L-亮氨酰-N-[(1S)-1-甲酰基-3-甲基丁基]-L-亮氨酰胺]存在的情况下,苄普地尔和W-7没有进一步增加I(Na)。苄普地尔、W-7和MG132但不是KN93以浓度依赖性方式显著降低20S蛋白酶体活性。
我们得出结论,治疗浓度的苄普地尔长期作用于心肌细胞会抑制钙调蛋白的作用,从而减少Na(v)1.5α亚基的降解,进而增加钠电流。